Biocon Yet to Decide on Biocon Biologics' Merger and IPO

Biocon Ltd. is currently evaluating strategic options for restructuring, including the merger of its subsidiary Biocon Biologics Limited (BBL) and an Initial Public Offering (IPO). The company had announced the formation of a committee to evaluate these options in May 2025. The committee is still in the process of evaluating the best value creation option. At present, there is no material event or information that requires disclosure under SEBI regulations. Biocon is committed to adhering to the highest standards of governance and disclosure and will make appropriate disclosures as and when required.